Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Howard A. Burris et al.|NEJM Evidence|2022Cited by 1.1k
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
CD34 cell dose in granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen–identical sibling transplantationJan Maciej Zaucha, Beverly Torok‐Storb, Theodore A. Gooley et al.|Blood|2001Cited by 227
Chemotherapy-Related Toxicity, Nutritional Status and Quality of Life in Precachectic Oncologic Patients with, or without, High Protein Nutritional Support. A Prospective, Randomized StudyMonika Ziętarska, Sylwia Małgorzewicz, Joanna Krawczyk-Lipiec et al.|Nutrients|2017Cited by 67
Nutritional status assessment in colorectal cancer patients qualified to systemic treatmentMonika Ziętarska, Sylwia Małgorzewicz, Joanna Krawczyk-Lipiec et al.|Współczesna Onkologia|2017Cited by 30